Insight Molecular Diagnostics
IMDX
32 hedge funds and large institutions have $22M invested in Insight Molecular Diagnostics in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
1,184% more capital inflows, than outflows
Capital inflows: $285K | Capital outflows: $22.2K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
7% more funds holding
Funds holding: 30 → 32 (+2)
0.15% more ownership
Funds ownership: 10.73% → 10.89% (+0.15%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$150K |
| 2 |
Family Management
New York
|
+$65.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.5K |
| 4 |
BlackRock Fund Advisors
San Francisco,
California
|
+$24.6K |
| 5 |
Morgan Stanley
New York
|
+$6.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13K |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$4.4K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$4K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$551 |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$220 |
IMDX Hedge Fund Activity: Q4 2016 in Review
32 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q4 2016, worth a combined $22M — up 42% from $15.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IMDX positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Manatuck Hill Partners, adding an estimated $150K. The largest seller was Deutsche Bank, cutting an estimated $13K.
- 32 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q4 2016, up from 30 in Q3 2016.
- Funds reported $22M of Insight Molecular Diagnostics stock for Q4 2016, up 42% quarter-over-quarter.
- 5 funds opened new Insight Molecular Diagnostics positions in Q4 2016 and 3 closed out, a net change of +2 holders.
- The largest Insight Molecular Diagnostics buyer in Q4 2016 was Manatuck Hill Partners, an estimated $150K added.
- The largest Insight Molecular Diagnostics seller in Q4 2016 was Deutsche Bank, an estimated $13K sold.
Based on aggregated 13F filings for Q4 2016.